European Journal of Dermatology
MENUCutaneous Kaposi sarcoma during treatment with superpotent topical steroids and methotrexate for bullous pemphigoid: three cases Volume 27, numéro 4, July-August 2017
Auteurs
3 Department of Dermatology,
Hospital of Tours,
Avenue de la République,
37044 Tours Cedex 9,
France
Hospital of Tours,
Avenue de la République,
37044 Tours Cedex 9,
France
6 International Agency for Research on Cancer,
Infections and Cancer Biology Group,
150 Cours Albert Thomas,
69372 Lyon CEDEX 08,
France
Infections and Cancer Biology Group,
150 Cours Albert Thomas,
69372 Lyon CEDEX 08,
France
7 Laboratory “Biologie des Infections à Polyomavirus”,
ISP 1282,
INRA-University François,
Rabelais,
Tours,
France
ISP 1282,
INRA-University François,
Rabelais,
Tours,
France
* Reprints
- Mots-clés : bullous pemphigoid, human herpes virus 8, Kaposi sarcoma, methotrexate, topical steroids
- DOI : 10.1684/ejd.2017.3027
- Page(s) : 369-74
- Année de parution : 2017
Background
Iatrogenic Kaposi sarcoma (KS) has previously been reported in patients with bullous pemphigoid (BP), in relation to systemic steroids.